Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Amazon

Home Depot

Moderna

Starbucks

These stocks all dropped in the double digits last year. But their future prospects are brilliant.

5 Potentially Explosive Stocks to Buy in 2023

Inmode Ltd

These two companies are in very different situations but could generate significant returns for investors.

More Likely to 5X First: CRISPR Therapeutics vs. InMode

Prime Medicine Inc

CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't produce double-strand breaks in DNA.

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics

Shopify

At their beaten-down valuations, these stocks have the potential to deliver some impressive returns.

2 Growth Stocks You May Regret not Buying Right Now

ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in B. Riley Securities' 3rd Annual Oncology Conference on Wednesday, January 18, 2023, at 10:30 a.m. ET.

CRISPR Therapeutics to Participate in B. Riley Securities' 3rd Annual Oncology Conference

Vertex Pharmaceuticals

Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years

AbCellera Biologics

AST SpaceMobile

Beam Therapeutics

Editas Medicine

JFrog

HashiCorp

Maxar Technologies

MongoDB

Intellia Therapeutics

UiPath

Planet Labs

Rocket Lab USA

Sumo Logic

Tesla

While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.

10 Potential 10x Return Stocks For The Next 10 Years

CRISPR Therapeutics AG is a gene editing company based on CRISPR/Cas9 technology. CRISPR method seems to be the preferred in Gene Editing.

CRISPR Therapeutics: 2023 Could Be The Right Year

PayPal

These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year.

3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street

Teladoc

Both stocks have fallen brutally this year, but only one has a chance to recover soon.

1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)

Biogen

Pharma and biotech stocks are enjoying tailwinds as part of the broad market rally today.

3 Biotech Stocks to Watch Heading Into 2023

The gene-editing stock still has plenty of promise.

Could CRISPR Therapeutics Help You Become a Millionaire?

Crispr expects to make history in 2023 with a first-ever request in gene-editing technology by the same name, which could stoke shares. The post Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?

Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?

Roku

These businesses aren't in as much trouble as their stock returns suggest that they are.

3 Cathie Wood Stocks That Could Make Big Comebacks in 2023

ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding brings extensive leadership experience in biopharma business development and corporate strategy and joins CRISPR Therapeutics to lead the Company's business development operations.

CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development

Zoetis

These stocks could have significant upside opportunities ahead.

3 Beaten-Down Stocks That Could Explode Higher in 2023

Harpoon Therapeutics Inc

Knightscope

Microvast Holdings

Rent the Runway

Soligenix

Solo Brands

There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfolio.

7 Stocks to Add to Your 10x Watchlist

-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial-

CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®

BOSTON and ZUG, Switzerland--( BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced an oral, encore presentation of clinical data from patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT) treated with the investigational therapy exagamglogene autotemcel (exa-cel) in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study. Vertex will also present new health economics and outcomes research from multiple studies in patients with SCD and TDT.

Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

Carnival

Disney

It's time to hit the best sale in town, and that involves many top stocks.

5 Best Bargain Stocks to Buy Before 2023

A strong cash position could offset some of the near-term risks that come with owning the biotech.

Is CRISPR Therapeutics a Buy?

3 Fierce Stocks That Are Screaming Buys in December

NIKE

These top players are ripe for recovery -- and long-term growth.

Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?

ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 2022 BMO Growth & ESG Conference on Wednesday, December 7, 2022, at 1:00 p.m. ET.

CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference

News for CRISPR Therapeutics Stock (CRSP)